Enzootic Pneumonia (swine)

Enzootic pneumonia is a chronic respiratory disease of swine caused primarily by the bacterium Mycoplasma hyopneumoniae, representing one of the most economically significant health challenges facing pig producers worldwide. This condition is characterized by a persistent, low-grade pneumonia that spreads slowly through susceptible populations and predisposes affected animals to secondary infections with other respiratory pathogens. The disease is called enzootic because of its endemic nature in pig populations, where it tends to persist at a steady level rather than causing dramatic epidemic outbreaks. Understanding the biology of Mycoplasma hyopneumoniae and implementing effective control strategies is essential for managing respiratory health and optimizing production efficiency in swine operations.

Enzootic pneumonia affects pigs of all ages, though clinical disease is most commonly observed in growing and finishing pigs between eight and twenty-six weeks of age. The condition is ubiquitous in swine-producing regions around the world, with the majority of conventional pig herds testing positive for Mycoplasma hyopneumoniae infection. Prevalence studies consistently show that lung lesions consistent with enzootic pneumonia are present in a substantial percentage of pigs at slaughter, demonstrating the widespread nature of subclinical infection. The chronic nature of the disease and its tendency to cause cumulative lung damage over time means that even low-level endemic infection has significant production impacts across affected populations.

The economic and welfare impact of enzootic pneumonia is substantial and multifaceted. Infected pigs show reduced growth rates, poorer feed conversion efficiency, and increased variation in body weight that complicates management and marketing decisions. The primary infection also predisposes animals to secondary bacterial infections, contributing to the porcine respiratory disease complex that causes additional mortality and treatment costs. Medication expenses for both treatment and prevention represent significant ongoing costs for affected operations. From a welfare perspective, affected pigs experience chronic cough, reduced exercise tolerance, and general malaise that compromises their quality of life. The pervasive nature of the infection in global pig populations means these impacts affect the majority of commercial swine production.

Enzootic pneumonia is manageable through a combination of vaccination, medication, and management practices, though complete elimination of infection is challenging in most production systems. Early recognition of clinical signs and prompt implementation of control measures helps limit disease impact and secondary infection complications. Prevention and control programs must address both the primary Mycoplasma hyopneumoniae infection and the secondary pathogens that complicate the disease. Veterinary involvement in developing comprehensive respiratory health programs tailored to specific farm conditions is essential for optimizing outcomes. The chronic nature of the condition requires ongoing attention to respiratory health management rather than one-time interventions.

The primary cause of enzootic pneumonia is infection with Mycoplasma hyopneumoniae, a small bacterium lacking a cell wall that colonizes the respiratory epithelium of pigs. This organism attaches to the cilia of respiratory tract cells, damaging them and impairing the normal mucociliary clearance mechanism that protects the lungs from inhaled particles and pathogens. The damage to respiratory defenses creates an environment conducive to secondary infections with other bacteria, most notably Pasteurella multocida, Actinobacillus pleuropneumoniae, Streptococcus suis, and Haemophilus parasuis. These secondary infections often cause more severe clinical disease than the primary mycoplasmal infection alone. Viral pathogens, including porcine reproductive and respiratory syndrome virus and swine influenza virus, also interact synergistically with Mycoplasma hyopneumoniae to worsen respiratory disease.

While enzootic pneumonia is not a hereditary condition, certain pig genetics may influence susceptibility to infection and disease severity. Some breeding lines have demonstrated greater resistance to respiratory disease in general, possibly through variations in immune response or respiratory tract structure. However, the widespread susceptibility of modern commercial pig genetics to Mycoplasma hyopneumoniae means that genetic resistance is not a reliable control measure at this time. Selection for improved respiratory health is complicated by the multiple pathogens involved and the environmental influences on disease expression. Future genomic selection tools may enable more targeted improvement in mycoplasma resistance.

Environmental and management factors strongly influence the incidence and severity of enzootic pneumonia. High stocking densities increase transmission rates by placing susceptible animals in close contact with infected individuals. Poor ventilation elevates pathogen concentrations in the air and stresses respiratory defenses. Temperature fluctuations and drafts cause physiological stress that increases susceptibility to infection. Multi-site production systems have advantages in controlling enzootic pneumonia when proper biosecurity is maintained, while continuous flow systems with mixing of animals from different sources facilitate disease spread. The quality of air in pig buildings, including dust and ammonia levels, interacts with mycoplasmal infection to worsen respiratory disease.

Risk factors for enzootic pneumonia include multiple production and management variables. Mixing pigs from different sources or age groups brings together animals with different infection and immunity status, promoting disease transmission. Weaning stress compromises immune function at a critical time when piglets may be exposed to infection. Transportation stress similarly increases susceptibility. Concurrent infections with other respiratory or systemic pathogens amplify the impact of Mycoplasma hyopneumoniae. Large herd size increases the probability of infection being present and provides more opportunities for transmission. Seasonal factors may influence disease patterns, with some operations seeing increased respiratory problems during cold weather when ventilation is reduced.

The pathophysiology of enzootic pneumonia involves a cascade of events following initial colonization. Mycoplasma hyopneumoniae attaches to respiratory epithelial cells and damages cilia, reducing the ability of the respiratory tract to clear particles and pathogens. The organism also modulates the host immune response, creating chronic inflammation while evading complete elimination. Lymphoid hyperplasia around airways is a characteristic pathological finding, representing the ongoing immune response to persistent infection. The combination of impaired clearance and chronic inflammation creates ideal conditions for secondary bacterial colonization. As the disease progresses, areas of lung consolidation develop that reduce respiratory capacity and affect oxygen exchange. The cumulative lung damage accounts for the production impacts seen in affected populations.

Early warning signs of enzootic pneumonia are often subtle and easily overlooked in busy production settings. A dry, nonproductive cough that increases gradually in frequency through a group is typically the first clinical indication of disease. The cough is often more noticeable during periods of activity or when pigs are disturbed, and may be missed if observations are made only during quiet periods. Slight decreases in growth rate compared to expected performance may be detected through careful monitoring but are often attributed to other causes. Increased respiratory rate at rest, though difficult to assess in group housing, suggests developing respiratory compromise. Slightly reduced feed intake may precede more obvious clinical signs.

Common symptoms of established enzootic pneumonia include the characteristic chronic dry cough that gives the condition its clinical identity. This cough may persist for weeks or months in affected groups, typically affecting a proportion of animals rather than the entire population. Affected pigs show reduced growth rates and poor feed conversion that may only become apparent through careful production record analysis. Variation in body weight within groups increases as some individuals are more severely affected than others. Respiratory rate is elevated, particularly during exertion or in warm conditions. General condition may appear slightly poor, with rough hair coats and reduced body condition compared to unaffected contemporaries.

Behavioral changes in pigs with enzootic pneumonia reflect their chronic respiratory compromise and reduced overall wellness. Affected animals are often less active than their healthy counterparts, spending more time lying down and less time engaged in exploratory or social behaviors. Competition for feed may be reduced as affected pigs have less energy for aggressive interactions. Some pigs may show preference for areas of the pen with better air quality or cooler temperatures. The subtle nature of these behavioral changes means they are easily missed without careful observation and comparison to unaffected groups.

Physical examination findings in enzootic pneumonia cases include elevated respiratory rate that is typically more obvious during or after exertion. Auscultation of the chest reveals increased breath sounds and may detect areas of consolidation with reduced airflow. Body condition is often slightly reduced compared to age-matched unaffected pigs. Rectal temperature may be normal or only slightly elevated in uncomplicated mycoplasmal infection, though fever increases when secondary bacterial infections are present. Nasal discharge is uncommon with primary mycoplasmal infection but may appear with secondary infections. The characteristic cough can often be elicited by applying pressure to the trachea during examination.

Symptom progression in enzootic pneumonia typically follows a chronic course over weeks to months. Initial infection spreads slowly through the group as susceptible pigs acquire the organism from infected penmates. Coughing increases in frequency and affects a growing proportion of the population. Production impacts accumulate as lung damage increases and affects an expanding number of animals. Secondary bacterial infections may cause acute exacerbations with increased severity of signs, fever, and mortality. Without intervention, the cumulative impact on growth rate and feed efficiency can be substantial by the time pigs reach market weight. The chronic nature of the disease means that lung lesions at slaughter may be present even in groups that appeared clinically mild.

Emergency symptoms requiring immediate veterinary attention occur when secondary infections complicate the primary mycoplasmal disease. Severe respiratory distress with labored breathing and cyanosis indicates serious lung compromise requiring urgent intervention. High fever suggests significant bacterial infection requiring aggressive antibiotic therapy. Sudden deaths or rapidly increasing mortality rates demand immediate investigation and treatment. Multiple pigs showing acute severe signs simultaneously indicates a complicated outbreak requiring comprehensive diagnostic workup and treatment response. Any deterioration from the typical chronic mild presentation of enzootic pneumonia warrants prompt veterinary evaluation to address potential complications.

Clinical examination for enzootic pneumonia relies on recognition of the characteristic chronic cough and assessment of respiratory health across the affected population. Observation of pigs at various times of day and during different activities helps characterize the cough pattern and estimate the proportion of affected animals. Physical examination of representative individuals provides information about disease severity in clinical cases. Production record review reveals growth rate impacts and feed efficiency losses that may not be apparent from clinical observation alone. Assessment of environmental conditions including air quality, ventilation, and stocking density provides context for respiratory disease patterns.

Diagnostic testing confirms Mycoplasma hyopneumoniae infection and helps distinguish it from other respiratory pathogens. Polymerase chain reaction testing on nasal swabs, tracheal swabs, or lung tissue provides sensitive detection of the organism. Serological testing detects antibodies to Mycoplasma hyopneumoniae and can be used for population-level screening to determine infection status. Enzyme-linked immunosorbent assays are commonly used for serological surveillance. Bacterial culture is challenging because Mycoplasma hyopneumoniae is fastidious and slow-growing, limiting its practical utility in routine diagnosis. Lung scoring at slaughter, using standardized systems to quantify the extent of lung lesions, provides valuable retrospective data on respiratory health and disease impact.

Differential diagnosis for enzootic pneumonia includes other causes of respiratory disease in swine that may present similarly. Porcine reproductive and respiratory syndrome causes respiratory signs and often occurs concurrently with mycoplasmal infection. Swine influenza causes acute respiratory disease with cough and fever. Actinobacillus pleuropneumoniae causes severe pleuropneumonia that may complicate mycoplasmal infection or occur independently. Pasteurella multocida infection frequently accompanies Mycoplasma hyopneumoniae as a secondary invader. Dust and ammonia exposure cause respiratory signs that may be confused with or compound infectious disease. Comprehensive diagnostic workup typically reveals the multiple pathogens often present in porcine respiratory disease complex.

Herd-level diagnostics are essential for understanding enzootic pneumonia epidemiology and developing effective control programs. Serological profiling across different age groups reveals the timing of infection and helps target interventions. Systematic lung scoring at slaughter provides objective data on respiratory disease impact that can be tracked over time to evaluate control program effectiveness. Monitoring production parameters including growth rate, feed efficiency, mortality, and treatment costs quantifies the economic impact of respiratory disease. Environmental monitoring of air quality supports assessment of contributing factors. Regular veterinary consultation and diagnostic testing enables adaptive management of respiratory health programs based on current herd status.

Emergency treatment for severe respiratory disease complicated by secondary infections requires prompt aggressive intervention. Severely affected pigs should be identified and treated individually with injectable antibiotics to ensure adequate dosing. Broad-spectrum antibiotics effective against common secondary pathogens including Pasteurella multocida and other gram-negative bacteria are appropriate initial choices. Anti-inflammatory medication helps reduce fever and inflammation associated with severe infection. Supportive care including ensuring access to water and feed, maintaining comfortable environmental conditions, and reducing competition stress supports recovery. Separation of severely affected individuals from the group reduces stress and prevents pathogen spread.

Medical management of enzootic pneumonia combines treatment of clinical cases with strategic population-level interventions. Antibiotics effective against Mycoplasma hyopneumoniae include macrolides such as tilmicosin, tulathromycin, and tylosin, as well as tetracyclines, lincosamides, and fluoroquinolones where permitted. Individual treatment of clinical cases with injectable products provides reliable dosing for animals that may have reduced appetite. Water medication enables treatment of groups during outbreaks, though adequate water intake must be ensured for effective dosing. Feed medication provides strategic treatment during high-risk periods or for control of endemic disease. Treatment duration varies by product and severity, with typical courses ranging from three to seven days. Withdrawal times must be carefully observed for all medications to ensure food safety compliance.

Surgical intervention has no role in treating enzootic pneumonia, as the condition involves diffuse lung infection rather than focal lesions amenable to surgical correction. Treatment relies entirely on antimicrobial therapy, supportive care, and management interventions to control disease and support recovery.

Supportive care complements antimicrobial treatment in managing enzootic pneumonia. Ensuring adequate ventilation and air quality reduces the respiratory burden on compromised lungs. Maintaining appropriate stocking density reduces transmission and stress. Providing palatable, easily consumed feed supports nutrition in animals with reduced appetite. Clean water access is essential for both hydration and effective water medication delivery. Temperature management within the thermal comfort zone reduces additional stress on affected animals. Minimizing handling and movement stress during acute disease allows energy to be directed toward recovery.

Herd treatment protocols address enzootic pneumonia at the population level through strategic medication programs. Pulse dosing of water or feed medication during high-risk periods such as weaning, mixing, and transportation reduces disease impact. Continuous low-level medication may be used in severely affected herds but carries concerns regarding antimicrobial resistance and cost. Strategic timing of treatment based on expected infection timing, determined through serological profiling, optimizes intervention effectiveness. Combination of treatment with vaccination provides both immediate disease control and longer-term immunity development. Coordinated treatment and management interventions addressing all components of porcine respiratory disease complex provide better outcomes than targeting mycoplasma alone.

Treatment decisions for enzootic pneumonia must balance immediate clinical needs with longer-term herd health goals and antimicrobial stewardship concerns. Individual treatment of clinical cases remains appropriate and important for both animal welfare and productivity. Population-level medication programs should be used strategically rather than continuously to minimize antimicrobial resistance development. The economic analysis of treatment costs versus production losses guides medication program intensity. Integration of vaccination into control programs often allows reduction in antimicrobial use while maintaining disease control. Veterinary involvement in treatment planning ensures appropriate drug selection, dosing, and timing while addressing regulatory requirements and resistance concerns.

Recovery timeline for enzootic pneumonia varies depending on disease severity, the presence of secondary infections, and the effectiveness of treatment and environmental improvements. Mild cases showing improvement in cough and appetite within days of treatment initiation may return to normal production within one to two weeks. More severe cases with established lung consolidation require extended recovery periods of three to four weeks or longer. Cases complicated by secondary bacterial infections require complete resolution of the bacterial component before meaningful recovery from the underlying mycoplasmal infection can occur. The chronic nature of Mycoplasma hyopneumoniae infection means that the organism may persist in recovered animals even after clinical signs resolve.

Post-treatment care and monitoring focuses on supporting continued recovery and detecting any relapse or complications. Observation for return of coughing or respiratory distress identifies animals requiring additional treatment. Growth rate monitoring helps quantify recovery and identify individuals with persistent subclinical effects. Air quality and environmental management should be optimized to support respiratory healing. Reduction of stressors including overcrowding, mixing, and temperature extremes gives recovering animals the best chance for full recovery. Follow-up veterinary assessment approximately two weeks after treatment evaluates response and guides decisions about additional interventions.

Prognosis factors for enzootic pneumonia include the extent of lung damage at treatment initiation, the presence and type of secondary infections, and the effectiveness of environmental management during recovery. Early treatment before extensive lung consolidation develops carries the best prognosis for return to normal production. Cases complicated by aggressive secondary pathogens such as Actinobacillus pleuropneumoniae have more guarded outlooks. The quality of air and management conditions during recovery significantly influences outcomes. Young animals generally have better healing capacity than older pigs with potentially more chronic lung damage.

Return to production considerations for pigs recovered from enzootic pneumonia include assessment of residual lung damage and its likely impact on subsequent performance. Lung scoring at slaughter provides definitive information about disease impact, but production monitoring of recovered groups offers earlier indication of lasting effects. Growth rates and feed efficiency should be tracked to determine whether affected animals will reach target weights on schedule. Marketing decisions may need to account for variable recovery within groups. For breeding animals, respiratory capacity for the demands of gestation and lactation should be considered. Documentation of disease events and outcomes supports ongoing improvement of respiratory health programs.

Vaccination protocols form a cornerstone of enzootic pneumonia prevention in most modern swine production systems. Commercial vaccines against Mycoplasma hyopneumoniae are widely available and provide meaningful reduction in clinical disease severity and lung lesion development. Vaccination timing should be optimized based on expected infection timing in the specific production system, typically targeting immunization before natural exposure occurs. Single-dose and two-dose vaccination protocols are available, with two-dose programs potentially providing superior protection. Sow vaccination programs can provide maternal antibody protection to piglets during the early nursing period. Combination vaccines addressing multiple respiratory pathogens simplify vaccination programs while providing broader protection.

Biosecurity measures can prevent introduction of Mycoplasma hyopneumoniae to naive herds or specific pathogen free populations. Closed herd policies that limit introduction of outside animals prevent new strain introduction. When additions are necessary, sourcing from herds with known health status reduces introduction risk. Quarantine and testing of incoming animals before introduction to the main herd enables detection of infection before exposure occurs. Geographic isolation from other pig operations reduces the risk of airborne transmission between farms. Personnel biosecurity including shower-in protocols and farm-specific clothing limits human-mediated pathogen movement.

Nutritional prevention strategies support immune function and respiratory health to optimize response to infection and vaccination. Adequate protein and energy intake supports robust immune responses to both natural infection and vaccination. Vitamin and mineral supplementation at appropriate levels ensures immune system cofactors are available. Feed form and quality influence dust generation that can compound respiratory challenges. Avoiding nutritional deficiencies or excesses that could compromise immune function or respiratory health provides a foundation for disease resistance.

Management practices significantly influence enzootic pneumonia transmission and impact. All-in-all-out production with thorough cleaning and disinfection between groups breaks transmission chains and allows naive populations to be established. Multi-site production with separation of breeding, nursery, and finishing phases limits infection spread from endemic breeding herds to younger pigs. Reduced stocking density decreases pathogen transmission and improves air quality. Optimal ventilation provides fresh air while maintaining temperature and minimizing drafts. Minimizing mixing of pigs from different sources reduces transmission opportunities. Stress reduction through appropriate handling, temperature management, and disease prevention supports immune function.

Quarantine and testing protocols support maintenance of mycoplasma-negative status or controlled introduction to positive herds. New animal introductions should undergo isolation periods sufficient to detect infection before joining the main herd. Serological testing during quarantine identifies infected individuals. For herds attempting elimination programs, testing enables monitoring of progress toward negative status. Gilt acclimation programs that intentionally expose replacement animals to herd pathogens under controlled conditions can help stabilize immunity before farrowing. Regular serological profiling of the production population monitors infection dynamics and guides program adjustments.

Daily management and monitoring for enzootic pneumonia control requires consistent attention to respiratory health indicators across the production system. Walking through barns with attention to cough frequency and pattern provides ongoing surveillance for changing disease status. Observation of appetite, activity, and general demeanor helps identify individuals or groups requiring intervention. Feed and water consumption monitoring reveals early disease impacts that may precede obvious clinical signs. Temperature assessment of representative animals or groups with elevated coughing helps detect secondary infections requiring treatment. Documentation of observations supports trend analysis and veterinary consultation.

Housing and environmental management directly impacts enzootic pneumonia transmission and severity. Ventilation systems must provide adequate fresh air exchange to dilute airborne pathogen loads while maintaining temperature within the thermal comfort zone. Air quality management including dust and ammonia control reduces respiratory stress that compounds infectious disease. Temperature consistency without drafts or wide fluctuations reduces physiological stress on pigs. Stocking density management balances production efficiency with disease control considerations. Building design and room sizing that support all-in-all-out management enables production practices that limit disease transmission.

Herd health programs for enzootic pneumonia integrate vaccination, medication, and management into comprehensive respiratory health strategies. Vaccination protocols should be designed based on herd-specific infection timing and disease patterns. Strategic medication programs target high-risk periods without excessive continuous antimicrobial use. Environmental management addresses contributing factors including air quality, stocking density, and temperature control. Production flow management using all-in-all-out or multi-site approaches limits pathogen transmission. Regular veterinary review of respiratory health status and program effectiveness enables adaptive management. Coordination with other health programs including parasite control, reproductive management, and biosecurity creates comprehensive herd health support.

Record keeping and monitoring systems support data-driven management of enzootic pneumonia. Treatment records tracking medication use by group, dose, and indication enable analysis of disease patterns and treatment effectiveness. Production records including growth rates, feed efficiency, and mortality quantify disease impact and program value. Lung scoring data from slaughter plants provides objective measurement of respiratory disease over time. Serological monitoring data reveals infection timing and immunity patterns. Vaccination and medication program documentation ensures consistency and enables evaluation. Regular analysis of accumulated data guides program refinement and improvement.

Economic considerations for enzootic pneumonia management include evaluation of prevention and treatment costs against production impacts. Vaccination costs typically provide positive returns through reduced clinical disease, improved growth, and better feed efficiency. Medication program costs must be weighed against production benefits and antimicrobial stewardship concerns. Facility improvements supporting better air quality and disease control represent capital investments with potentially significant returns. Production losses from uncontrolled disease, including reduced growth rates, increased mortality, and treatment costs, provide economic justification for prevention investments. Regular cost-benefit analysis of respiratory health program components guides resource allocation decisions.

No specific pig breeds demonstrate genetic immunity or particular susceptibility to enzootic pneumonia, as Mycoplasma hyopneumoniae is capable of infecting all swine genetics. Modern commercial pig breeds and crossbreeds show similar susceptibility to infection under comparable management conditions. Some breeding companies have pursued selection for improved respiratory health, though progress is challenging due to the environmental influences on disease expression and the multiple pathogens involved in porcine respiratory disease complex. Heritage breeds maintained in less intensive production systems may appear less affected, though this likely reflects different management and exposure levels rather than genetic resistance.

Production type considerations influence enzootic pneumonia exposure and impact more than breed genetics. Intensive commercial production systems with large groups and continuous throughput face ongoing endemic infection challenges. Breeding herds typically establish endemic infection that persists across generations. Nursery and growing pig phases see active disease transmission as naive pigs encounter infected penmates. Finishing operations receive pigs with variable infection and immunity status depending on source farm programs. Extensive or alternative production systems with smaller groups, outdoor access, and single-source genetics may experience different infection dynamics.

Genetic selection and testing for enzootic pneumonia resistance remains limited but is an area of ongoing research interest. Some breeding programs track respiratory disease incidence and include health information in selection indices. Genomic studies have identified genetic regions potentially associated with respiratory disease resistance, though practical application in selection programs is not yet established. Selection for overall robustness and immune function may provide indirect benefits for mycoplasma resistance. Testing of breeding stock for current infection status can inform herd health management but does not indicate genetic resistance. Future developments in genomic selection may enable more targeted improvement in mycoplasma resistance.

Commonly co-occurring conditions with enzootic pneumonia constitute the porcine respiratory disease complex, a major health challenge in swine production. Porcine reproductive and respiratory syndrome virus infection frequently accompanies mycoplasmal pneumonia and causes synergistic damage to respiratory defenses. Swine influenza virus contributes to respiratory disease burden and may precipitate secondary bacterial infections. Porcine circovirus type 2 causes immunosuppression that enhances susceptibility to mycoplasma and other pathogens. Bacterial infections including Pasteurella multocida, Streptococcus suis, Haemophilus parasuis, and Actinobacillus pleuropneumoniae commonly complicate mycoplasmal pneumonia. Environmental factors including dust and ammonia exposure compound infectious respiratory disease.

Conditions with similar symptoms that must be differentiated from enzootic pneumonia include other causes of chronic cough and respiratory compromise in swine. Swine influenza causes acute respiratory disease with cough but typically affects groups more synchronously than the slowly spreading mycoplasmal infection. Actinobacillus pleuropneumoniae causes severe pleuropneumonia with higher mortality than typical enzootic pneumonia. Dust-induced respiratory disease causes cough and respiratory signs without the infectious component. Parasitic migration through the lungs, particularly Ascaris suum larvae, causes transient respiratory signs. Comprehensive diagnostic workup is usually necessary to identify all contributing pathogens in respiratory disease cases.

Complications and sequelae of enzootic pneumonia include both immediate disease complications and long-term production impacts. Secondary bacterial pneumonia with increased severity and mortality represents the most significant acute complication. Chronic lung consolidation with permanent reduction in respiratory capacity affects lifetime performance. Pleuritis and pleural adhesions may develop following complicated pneumonia. Abscessation in chronic cases creates foci of persistent infection. Growth retardation and poor feed efficiency persist even after clinical signs resolve, resulting in delayed marketing and reduced profitability. Increased susceptibility to other diseases due to chronic immune system activation compounds overall health impacts.